BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

(TheNewswire)

VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxysTechnology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys" or"Company") is pleased to announce that Marianne Stanford,PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford wasVice President of R&D at the former IMV Inc, where she and herteam were responsible for the development of the DPX™ vaccineportfolio. This included the study of the unique mechanism of actionof the DPX platform and its safety, efficacy, and dosing schedules inpreclinical models. Under her leadership, Dr. Stanford’s team alsodemonstrated that combining DPX, cyclophosphamide and then PD-1blockade (using antibodies such as pembrolizumab, Merck’sKeytruda™) enhanced immunogenicity and thus efficacy in cancermodels.  Dr. Stanford and collaborators have published numerousstudies and she is named inventor on multiple patents related to theDPX platform and DPX formulations. This includes patents that exploreDPX compositions that express mRNA encoded by the nucleic acidcomponents in targeted cells.

Dr. Stanford was most recently the Chief Scientific Officer at MaraRenewables Corp., where she drove the commercialization of bio-basedomega-3 nutrition products for global markets and oversaw teams ofscientists across multiple research groups, from discovery science toapplication research. Prior to this role, Dr. Stanford was theAssistant Scientific Director at the Institute for Infection andImmunity at The Canadian Institutes of Health Research (CIHR),Canada's federal funding agency for health research, where shehelped build Canada’s national infectious disease research capacity.

Dr. Stanford holds a PhD in Microbiology and Immunology from DalhousieUniversity, complemented by postdoctoral fellowships in viralimmunotherapy and oncology.

BioVaxys President and Chief Operating Officer Kenneth Kovan, says"We are pleased to now have the support of Dr. Stanford.  Herdeep familiarity with the DPX platform and experience leading thedevelopment of DPX formulations for oncology and infectious diseasebrings significant internal strength to BioVaxys.  We areparticularly excited to further her work developing DPX as a deliveryplatform for mRNA and other polypeptides.”

About BioVaxys TechnologyCorp.

BioVaxys Technology Corp. ( www.biovaxys.com ), a biopharmaceuticals companyregistered in British Columbia, Canada, is a clinical-stagebiopharmaceutical company dedicated to improving patient lives withnovel immunotherapies based on the DPX™ immune-educating technologyplatform for treating cancers, infectious disease, antigendesensitization for food allergy, and other immunological diseases.Through a differentiated mechanism of action, the DPX platformdelivers instruction to the immune system to generate a specific,robust, and persistent immune response. The Company's clinicalstage pipeline includes maveropepimut-S (MVP-S), based on the DPXplatform, in Phase IIB clinical development for advancedRelapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinumresistant Ovarian Cancer. MVP-S delivers antigenic peptides fromsurvivin, a well-recognized cancer antigen commonly overexpressed inadvanced cancers, and also delivers an innate immune activator and auniversal CD4 T cell helper peptide. MVP-S has been well tolerated andhas demonstrated defined clinical benefit in multiple cancerindications as well as the activation of a targeted and sustained,survivin-specific anti-tumor immune response. BioVaxys is alsodeveloping DPX+SurMAGE, a dual-targeted immunotherapy combiningantigenic peptides for both the survivin and MAGE-A9 cancer proteinsto elicit immune responses to these two distinct cancer antigenssimultaneously, DPX-RSV for Respiratory Syncytial Virus, DPX+rPA forpeanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.

The Company does not assume any obligation to update theforward-looking statements of beliefs, opinions, projections, or otherfactors, should they change, except as required by law.

BioVaxys common shares are listed on the CSE under the stock symbol'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in theUS (OTCQB: BVAXF ). For more information, visit www.biovaxys.com andconnect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"

Chief Executive Officer

Phone: +1 740 358 0555

CautionaryStatements on Forward Looking Information

This news release includes certain"forward-looking information" and "forward-lookingstatements" (collectively "forward-looking statements")within the meaning of applicable securities legislation. Allstatements, other than statements of historical fact, included herein,without limitation, statements relating to the future operating orfinancial performance of the Company, are forward-looking statements.Forward-looking statements are frequently, but not always, identifiedby words such as "expects", "anticipates","believes", "intends", "estimates","potential", "possible", and similar expressions,or statements that events, conditions, or results "will","may", "could", or "should" occur or beachieved. Forward-looking statements in this news release relate to,among other things, the Offering, including the expected use ofproceeds from the Offering.There can be no assurance that such statements will prove to beaccurate, and actual results and future events could differ materiallyfrom those expressed or implied in such forward-lookingstatements.

Forward-looking statements reflectthe beliefs, opinions and projections on the date the statements aremade and are based upon a number of assumptions and estimates,primarily the assumption that BioVaxys will be successful indeveloping and testing vaccines, that, while considered reasonable byBioVaxys, are inherently subject to significant business, economic,competitive, political and social uncertainties and contingenciesincluding, primarily but without limitation, the risk thatBioVaxys' vaccines will not prove to be effective and/ or willnot receive the required regulatory approvals. With regards toBioVaxys' business, there are a number of risks that could affectthe development of its biotechnology products, including, withoutlimitation, the need for additional capital to fund clinical trials,its lack of operating history, uncertainty about whether its productswill complete the long, complex and expensive clinical trial andregulatory approval process for approval of new drugs necessary formarketing approval, uncertainty about whether its autologous cellvaccine immunotherapy can be developed to produce safe and effectiveproducts and, if so, whether its vaccine products will be commerciallyaccepted and profitable, the expenses, delays and uncertainties andcomplications typically encountered by development stagebiopharmaceutical businesses, financial and development obligationsunder license arrangements in order to protect its rights to itsproducts and technologies, obtaining and protecting new intellectualproperty rights and avoiding infringement to third parties and theirdependence on manufacturing by third parties.

Many factors, both known andunknown, could cause actual results, performance or achievements to bematerially different from the results, performance or achievementsthat are or may be expressed or implied by such forward-lookingstatements and the parties have made assumptions and estimates basedon or related to many of these factors. Such factors include, withoutlimitation, the risk that the Company does not use the proceeds fromthe Offering as currently expected. BioVaxys does not assume anyobligation to update the forward-looking statements of beliefs,opinions, projections, or other factors, should they change, except asrequired by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.